View More Recent Stories

Oct 7, 2015 07:00AM Horizon Pharma plc Announces That Three of the Leading Proxy Advisory Firms Recommend That Depomed Shareholders Provide Consent FOR the Special Meetings Requests
Oct 5, 2015 07:00AM Horizon Pharma plc Announces Expansion and Relocation of U.S. Corporate Headquarters
Oct 2, 2015 07:00AM Horizon Pharma plc Announces Settlement of RAYOS(R) (prednisone) Delayed-Release Tablets Patent Litigation With Actavis Laboratories FL Inc.
Sep 29, 2015 05:30AM Horizon Pharma plc Announces Leading Proxy Advisory Service, Glass Lewis & Co., Recommends Depomed Shareholders Provide Consent FOR the Two Special Meeting Requests
Sep 28, 2015 07:00AM Institutional Shareholder Services (ISS) Recommends Depomed Shareholders Provide Consent FOR the Two Special Meeting Requests
Sep 25, 2015 08:00AM Horizon Pharma plc Receives Positive CHMP Opinion for RAVICTI(R) (Glycerol Phenylbutyrate) Oral Liquid for the Treatment of Urea Cycle Disorders in Patients Greater Than Two Months of Age
Sep 10, 2015 08:30AM Horizon Pharma plc Has Commenced Solicitation of Depomed, Inc. Shareholders for Calling of Special Meetings
Sep 9, 2015 07:00AM Horizon Pharma plc to Present at the Morgan Stanley Global Healthcare Conference
Sep 8, 2015 07:00AM Horizon Pharma plc Commences Exchange Offer to Acquire All Depomed, Inc. Common Shares
Sep 2, 2015 07:00AM Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering PENNSAID(R) (Diclofenac Sodium Topical Solution) 2%
Aug 27, 2015 07:00AM Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering PENNSAID(R) 2%
Aug 20, 2015 07:00AM Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering VIMOVO(R) (Naproxen/Esomeprazole) Delayed Release Tablets
Aug 19, 2015 02:00PM Horizon Pharma plc to Amend Preliminary Solicitation Statement to Include Proposed Nominees for Depomed's Board
Aug 13, 2015 08:30AM Horizon Pharma plc Sends Letter to Depomed, Inc Board of Directors
Aug 7, 2015 04:05PM Horizon Pharma plc Names George Hampton Executive Vice President, Global Orphan Business Unit and International Operations
Aug 7, 2015 07:00AM Horizon Pharma plc Announces Record Second Quarter 2015 Financial Results
Aug 3, 2015 07:13AM Horizon Pharma plc Commences Process to Request a Special Meeting of Depomed, Inc. Shareholders
Jul 31, 2015 07:00AM Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering PENNSAID(R) (diclofenac sodium topical solution) 2%
Jul 27, 2015 07:00AM Horizon Pharma plc Announces Collaboration With Fox Chase Cancer Center to Study ACTIMMUNE(R) (interferon gamma-1b) in Combination With PD-1/PD-L1 Inhibitors in Various Forms of Cancer
Jul 20, 2015 07:00AM Horizon Pharma plc Expects Record Net Sales Results for Second Quarter 2015 and Raises Full-Year 2015 Net Sales and Adjusted EBITDA Guidance
Jul 9, 2015 07:00AM Horizon Pharma plc Names Tina E. Ventura Vice President, Investor Relations
Jul 7, 2015 11:32AM Biothera Pharmaceutical Inc. Announces Board of Directors
Jul 6, 2015 07:00AM Horizon Pharma plc Files Patent Infringement Lawsuits Against Five Companies for Filing Abbreviated New Drug Applications for PENNSAID(R) (Diclofenac Sodium Topical Solution) 2%
Jul 2, 2015 07:00AM Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering PENNSAID(R) (Diclofenac Sodium Topical Solution) 2%
Jun 23, 2015 07:00AM Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering RAVICTI(R) (Glycerol Phenylbutyrate) Oral Liquid
Jun 19, 2015 07:00AM Timothy P. Walbert Receives EY Entrepreneur Of The Year(R) 2015 Midwest Award
Jun 16, 2015 07:30AM Horizon Pharma plc Updates Presentation Time at the JMP Securities 2015 Life Sciences Conference
Jun 5, 2015 07:00AM Horizon Pharma plc Initiates Phase 3 Trial of ACTIMMUNE(R) (interferon gamma-1b) for the Treatment of People With Friedreich's Ataxia
View More Recent Stories